Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

234 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The AIB1 polyglutamine repeat does not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Spurdle AB, Antoniou AC, Kelemen L, Holland H, Peock S, Cook MR, Smith PL, Greene MH, Simard J, Plourde M, Southey MC, Godwin AK, Beck J, Miron A, Daly MB, Santella RM, Hopper JL, John EM, Andrulis IL, Durocher F, Struewing JP, Easton DF, Chenevix-Trench G; Australian Breast Cancer Family Study; Australian Jewish Breast Cancer Study; Breast Cancer Family Registry; Interdisciplinary Health Research International Team on Breast Cancer Susceptibility; Kathleen Cunningham Foundation Consortium for Research into Familial Breast Cancer; Epidemiological Study of Familial Breast Cancer Study Collaborators. Spurdle AB, et al. Among authors: kelemen l. Cancer Epidemiol Biomarkers Prev. 2006 Jan;15(1):76-9. doi: 10.1158/1055-9965.EPI-05-0709. Cancer Epidemiol Biomarkers Prev. 2006. PMID: 16434590
The androgen receptor CAG repeat polymorphism and modification of breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Spurdle AB, Antoniou AC, Duffy DL, Pandeya N, Kelemen L, Chen X, Peock S, Cook MR, Smith PL, Purdie DM, Newman B, Dite GS, Apicella C, Southey MC, Giles GG, Hopper JL, Chenevix-Trench G, Easton DF; EMBRACE Study Collaborators. Spurdle AB, et al. Among authors: kelemen l. Breast Cancer Res. 2005;7(2):R176-83. doi: 10.1186/bcr971. Epub 2004 Dec 16. Breast Cancer Res. 2005. PMID: 15743497 Free PMC article.
Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers.
Berchuck A, Schildkraut JM, Wenham RM, Calingaert B, Ali S, Henriott A, Halabi S, Rodriguez GC, Gertig D, Purdie DM, Kelemen L, Spurdle AB, Marks J, Chenevix-Trench G. Berchuck A, et al. Among authors: kelemen l. Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2141-7. Cancer Epidemiol Biomarkers Prev. 2004. PMID: 15598772
BRAF polymorphisms and the risk of ovarian cancer of low malignant potential.
Kelemen L, James M, Spurdle A, Campbell I, Chang-Claude J, Peel D, Anton-Culver H, Berchuck A, Schildkraut J, Whittemore A, McGurie V, DiCioccio RA, Duffy D, Chenevix-Trench G. Kelemen L, et al. Gynecol Oncol. 2005 Jun;97(3):807-12. doi: 10.1016/j.ygyno.2005.03.007. Gynecol Oncol. 2005. PMID: 15904951
234 results